Armata Pharmaceuticals, Inc. (ARMP)

Armata Pharmaceuticals, Inc. (ARMP) Healthcare & Pipeline Overview

Armata Pharmaceuticals, Inc. pioneers bacteriophage-based therapeutics targeting antibiotic-resistant infections, leveraging its proprietary technology to address critical needs in global healthcare. With a partnership with Merck & Co., the company develops synthetic bacteriophage candidates, positioning itself in the evolving landscape of infectious disease treatment.

What Is the Investment Thesis for ARMP?

Armata Pharmaceuticals presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The company's focus on bacteriophage therapy addresses a critical unmet need in the treatment of antibiotic-resistant infections, a market poised for significant growth. Key value drivers include the clinical progress of its lead candidates, AP-SA02, AP-PA02, and AP-PA03, with successful clinical trial outcomes potentially leading to substantial market value appreciation. The partnership with Merck & Co. provides validation of Armata's technology and offers potential revenue streams through milestone payments and royalties. However, the company's negative profit margin of -9554.2% highlights the financial challenges inherent in clinical-stage drug development. Upcoming clinical trial results and regulatory milestones represent significant catalysts, while potential setbacks in clinical development and competition from alternative therapies pose ongoing risks. Investors should carefully weigh the potential rewards against the inherent risks associated with biotechnology investments.

Based on FMP financials and quantitative analysis

ARMP Key Highlights

• Market Cap of $200.62M reflects investor valuation of Armata's pipeline and technology.
• Gross Margin of 72.2% indicates strong potential profitability upon commercialization of products.
• Beta of 1.39 suggests higher volatility compared to the overall market.
• Partnership with Merck & Co. validates Armata's technology and provides potential for future revenue streams.
• Focus on bacteriophage therapy addresses a critical unmet need in the treatment of antibiotic-resistant infections.

Who Are ARMP's Competitors?

ARMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ARMP's Key Strengths?

• Proprietary bacteriophage technology platform.
• Clinical-stage product pipeline targeting antibiotic-resistant infections.
• Partnership with Merck & Co. provides validation and resources.
• Focus on a critical unmet need in global healthcare.

What Are ARMP's Weaknesses?

• Negative profit margin reflects high R&D expenses.
• Reliance on clinical trial success for product approval.
• Limited commercialization experience.
• Potential for competition from alternative therapies.

What Could Drive ARMP Stock Higher?

• Clinical trial results for AP-SA02 in Staphylococcus aureus bacteremia.
• Clinical trial results for AP-PA02 in Pseudomonas aeruginosa infections.
• Clinical trial results for AP-PA03 in pneumonia.
• Potential milestone payments from Merck & Co. partnership.
• Regulatory submissions and approvals for lead product candidates.

What Are the Key Risks for ARMP?

• Financial-distress signal — its Altman Z-Score of -24.53 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures can delay or halt product development.
• Regulatory hurdles and delays in product approval.
• Competition from established pharmaceutical companies.
• Emergence of new antibiotic resistance mechanisms.
• Financial challenges associated with clinical-stage drug development.

What Are the Growth Opportunities for ARMP?

• Expansion of Bacteriophage Pipeline: Armata has the opportunity to expand its pipeline of bacteriophage-based therapeutics to target a broader range of antibiotic-resistant infections. This includes developing new candidates for indications beyond Staphylococcus aureus bacteremia, Pseudomonas aeruginosa, and pneumonia. The market for targeted therapies against specific bacterial strains is substantial, with potential for significant revenue growth as new products enter clinical development and commercialization. Timeline: Ongoing, with new candidates potentially entering clinical trials within the next 2-3 years.
• Strategic Partnerships and Collaborations: Armata can leverage strategic partnerships and collaborations with pharmaceutical companies and research institutions to accelerate the development and commercialization of its bacteriophage therapeutics. The existing partnership with Merck & Co. serves as a model for future collaborations, providing access to resources, expertise, and funding. Expanding these partnerships can significantly enhance Armata's ability to address the global challenge of antibiotic resistance. Timeline: Ongoing, with potential for new partnerships to be established within the next 1-2 years.
• Geographic Expansion: Armata has the opportunity to expand its geographic reach beyond its current focus on the United States. Antibiotic resistance is a global problem, and there is significant demand for innovative therapies in Europe, Asia, and other regions. Establishing a presence in these markets through partnerships, licensing agreements, or direct commercialization can drive substantial revenue growth. Timeline: Medium-term, with potential for expansion into new markets within the next 3-5 years.
• Advancements in Bacteriophage Technology: Continued advancements in bacteriophage technology, such as synthetic biology and phage engineering, can enhance the efficacy and specificity of Armata's therapeutics. This includes developing phages with improved targeting capabilities, reduced immunogenicity, and enhanced stability. Investing in research and development to advance its technology platform can provide Armata with a competitive advantage in the bacteriophage therapy field. Timeline: Ongoing, with continuous improvements in technology expected over the next several years.
• Regulatory Pathways and Approvals: Successful navigation of regulatory pathways and approvals for its lead product candidates is critical for Armata's growth. Obtaining regulatory approval from agencies such as the FDA and EMA will allow Armata to commercialize its products and generate revenue. Streamlining the regulatory process through close collaboration with regulatory agencies and strategic clinical trial design can accelerate the time to market and maximize the commercial potential of its therapeutics. Timeline: Near-term, with potential for regulatory submissions and approvals within the next 1-3 years.

What Opportunities Does ARMP Have?

• Expansion of bacteriophage pipeline to target additional infections.
• Strategic partnerships and collaborations with pharmaceutical companies.
• Geographic expansion into new markets.
• Advancements in bacteriophage technology to improve efficacy.

What Threats Does ARMP Face?

• Clinical trial failures can delay or halt product development.
• Regulatory hurdles and delays in product approval.
• Competition from established pharmaceutical companies.
• Emergence of new antibiotic resistance mechanisms.

What Are ARMP's Competitive Advantages?

• Proprietary bacteriophage-based technology.
• Clinical-stage product pipeline.
• Partnership with Merck & Co.
• Expertise in bacteriophage therapy.

What Does ARMP Do?

Armata Pharmaceuticals, Inc., founded with the vision of combating antibiotic resistance, is a clinical-stage biotechnology company dedicated to the discovery and development of targeted bacteriophage therapeutics. The company's core technology revolves around the use of bacteriophages—viruses that infect and kill bacteria—to treat infections that have become resistant to traditional antibiotics. This approach offers a potential solution to the growing global crisis of antibiotic resistance, which threatens to undermine modern medicine. Armata's product pipeline includes several clinical-stage candidates, such as AP-SA02, designed to treat Staphylococcus aureus bacteremia, a severe bloodstream infection. AP-PA02 targets Pseudomonas aeruginosa, a bacterium often associated with hospital-acquired infections, while AP-PA03 is being developed for the treatment of pneumonia. These product candidates are developed using Armata's proprietary bacteriophage-based technology, which allows for the identification and engineering of phages with specific antibacterial properties. In addition to its internal development programs, Armata has established a partnership with Merck & Co. to develop synthetic bacteriophage candidates targeting undisclosed infectious disease agents. This collaboration underscores the potential of Armata's technology and its ability to address a wide range of infectious diseases. Headquartered in Marina del Rey, California, Armata Pharmaceuticals is at the forefront of the bacteriophage therapy field, striving to deliver innovative solutions to combat the ever-increasing threat of antibiotic-resistant infections.

What Products and Services Does ARMP Offer?

• Develop targeted bacteriophage therapeutics.
• Focus on antibiotic-resistant infections.
• Utilize proprietary bacteriophage-based technology.
• Develop AP-SA02 for Staphylococcus aureus bacteremia.
• Develop AP-PA02 for Pseudomonas aeruginosa infections.
• Develop AP-PA03 for pneumonia.
• Partner with Merck & Co. for synthetic bacteriophage candidates.

How Does ARMP Make Money?

• Develop and commercialize bacteriophage therapeutics.
• Generate revenue through product sales.
• Collaborate with pharmaceutical companies for research and development.
• Receive milestone payments and royalties from partnerships.

What Industry Does ARMP Operate In?

Armata Pharmaceuticals operates within the biotechnology industry, specifically targeting the growing market for antibiotic-resistant infection treatments. The rise of antibiotic resistance poses a significant threat to global health, driving demand for novel therapeutic approaches like bacteriophage therapy. The competitive landscape includes companies developing traditional antibiotics, as well as those exploring alternative therapies such as antimicrobial peptides and immunotherapy. The global market for antibiotic resistance is projected to reach billions of dollars in the coming years, presenting a substantial opportunity for companies like Armata with innovative solutions.

Who Are ARMP's Key Customers?

• Hospitals and healthcare providers.
• Patients with antibiotic-resistant infections.
• Pharmaceutical companies through partnerships.

FY2026 estForward Outlook

Wall Street analysts project Armata Pharmaceuticals, Inc. revenue of about $2.2M for fiscal 2026, with EPS near $-3.81.

F-Score 3/9Financial Health

Armata Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.53 places it in the distress zone, a signal of elevated financial risk.

ROE 163%Key Financial Metrics

Return on equity for Armata Pharmaceuticals, Inc. stands at 162.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.64 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -94.7%, the inverse of the P/E and a quick read on earnings relative to price.

Armata Pharmaceuticals, Inc. (ARMP) Valuation Context

Valued at $200.62M, ARMP is classified as a micro-cap stock. Relative to its peer group, ARMP's quantitative score of 14/100 is below the peer average of 76/100.

Company Profile

Armata Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Marina del Rey, US. The company is led by CEO Deborah L. Birx. ARMP has traded publicly since 1994.

ARMP Financials

ARMP Latest News

ARMP Analyst Consensus

ARMP MoonshotScore

Common Questions About ARMP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources